About Abivax
Abivax is a publicly listed company based in Paris (France) founded in 2014. Therapeutics for chronic inflammatory diseases are developed. The company has 69 employees. Its website abivax.com draws about 39 thousand monthly visits. Abivax offers products and services including Obefazimod and Proprietary Chemical Library. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral.
Company details
Abivax was founded in 2014 in Paris, France, within the biotechnology sector. Therapeutics targeting chronic inflammatory diseases are developed, with operations focused on drug candidates for conditions such as ulcerative colitis and Crohns disease. The lead candidate, obefazimod, is utilized as an oral small molecule by which miR-124 expression is enhanced to regulate inflammatory responses. Additional indications are addressed through ongoing product development.
- Headquarters Paris, France
- Employees 69
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website abivax.com
- Social LinkedIn X
- Legal Name Abivax Sa
- Net Profit-$394.92 M (USD)-90.7as on Dec 31, 2025
- EBITDA-$293.22 M (USD)-35.38as on Dec 31, 2025
- Latest Funding Round$138.59M (USD), Post-IPO
Feb 2023
- InvestorsBpifrance
& 13 more
- Employee Count69
Products & Services of Abivax
Abivax offers a comprehensive portfolio of products and services, including Obefazimod and Proprietary Chemical Library.
Investigational oral molecule enhancing miR-124 for immune response regulation in diseases.
Collection of compounds for developing new inflammatory disease treatments through innovation.
Funding Insights of Abivax
- Total Rounds 5
- Last Round Post-IPO — $138.59M
- First Round $13.5M
(Jul 2019)
- Investors Count 14
All 5 funding rounds of Abivax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $138.59M | Post-IPO | – | – | |
| Sep 2022 | $49.14M | Post-IPO | – | – | |
| Jul 2021 | $96.64M | Post-IPO | – | – | – |
| May 2020 | $21.74M | Grant | – | – | |
| Jul 2019 | $13.5M | Post-IPO | – | – |
14 investors in total: 14 institutional.
Investors in Abivax
Abivax has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Bpifrance, Truffle Capital and TCG Crossover.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| tcgcrossover.com | ||||
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Deep Track Capital is engaged in biotechnology investment activities. | deeptrackcapital.com | Greenwich, United States | ||
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
VC & PE firm focused on healthcare sector | venrockcp.com | Palo Alto, United States | ||
Private equity firm focused on company buyouts | gppfunds.com | Greenwich, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Venture capital is provided to healthcare startups by Commodore Capital. | commodorecapital.com | New York, United States | ||
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States |
Investor details for Abivax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Abivax
40 people are tracked at Abivax (19 in leadership, 15 in board & advisors, 6 in team); the tracked headcount is 69.
| Name | Role | Group |
|---|---|---|
Pierre Courteille | Chief Commercial Officer & VP of Business Development | Leadership |
Trinidad Mesa | Finance & Accounting Director | Leadership |
Chris Rabbat | Vice President And Head Of Medical Affairs | Leadership |
Jérôme Denis | VP of Process Development & Manufacturing | Leadership |
Ida Hatoum | Chief People Officer | Leadership |
Marc De Garidel | Chief Executive Officer | Leadership |
Didier Scherrer | Chief Scientific Officer | Leadership |
Didier Blondel | EVP, CFO & Board Secretary | Leadership |
Julien Santo | Translational Research Director | Leadership |
Nadege Briancon-Eris | Senior Vice President, Program Management | Leadership |
Marcus Wilkes | Vice President - Business Development And Organizational Strategy | Leadership |
Phuong Tran | Director, Medical Affairs | Leadership |
Jennifer Fine | Senior Vice President Evidence Generation And HEOR | Leadership |
Hema Keshava | Senior Vice President Finance | Leadership |
Amy Adams | Director, Data Management | Leadership |
Laurence Desroys du Roure | Associate Director, Clinical Operations | Leadership |
Aude Garcel | R&d Director | Leadership |
David Zhang | Chief Strategy Officer | Leadership |
Fabio Cataldi | EVP And Chief Medical Officer | Leadership |
Philippe Pouletty | Chairman | Board & advisors |
20 more people are available in the full profile.
Complete people profiles for Abivax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Abivax
Abivax is a publicly listed company on the EURONEXT with ticker symbol ABVX in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Oct 2023
- Listed onNASDAQ: ABVX
- Listed entityAbivax SA
- Exchange sectorHealth technology
- ISINFR0012333284
- Share price77.75 EUR (+1.04% on the day) · 2026-10-14
- Market capitalisation6,735,461,906.00 EUR
- EPS (diluted, trailing year)-5.23 EUR
- Volume (last session)23,565
Financials of Abivax
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -336.1M EUR | -249.6M EUR | |
| 2024 | -176.2M EUR | -184.3M EUR | |
| 2023 | -147.7M EUR | -131.3M EUR | |
| 2022 | -60.7M EUR | -55.3M EUR | |
| 2021 | -41.4M EUR | -52.0M EUR |
Detailed financial statements for Abivax
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Abivax
4 dated milestones of Abivax across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Abivax is founded.
- Funding First funding round of $13.5M.
- Funding Latest funding round, Post-IPO, of $138.6M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Abivax
The website of Abivax (abivax.com) receives about 39.3K visits a month and ranks #727,495 among all websites worldwide, #826 in Biotechnology and Pharmaceuticals.
- Monthly visits39.3K
▲ 25.2% vs previous month
- Unique visitors12.7K
per month
- Global rank#727,495
among all websites
- Category rank#826
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit4.0
- Average visit1 min 03 sec
- DevicesDesktop 55% · Mobile 45%
Websites whose visitors overlap most with Abivax. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ab-science.com | 100% | 6.7K | #3,021,575 | View details | |
| biocentury.com | 98% | 85.7K | #514,907 | View details | |
| biopharmadive.com | 97% | 680.7K | #208,628 | View details | |
mypharma-editions.com | mypharma-editions.com | 97% | #4,774,463 | – | |
biotechinfo.fr | biotechinfo.fr | 97% | #9,575,314 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Abivax
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abivax
Complete news archive for Abivax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abivax
Abivax was founded in 2014 and raised its 1st funding round 5 years after it was founded.
Abivax is headquartered in Paris, France.
Abivax has 69 employees.
Abivax was founded in 2014 in Paris, France, within the biotechnology sector. Therapeutics targeting chronic inflammatory diseases are developed, with operations focused on drug candidates for conditions such as ulcerative colitis and Crohns disease. The lead candidate, obefazimod, is utilized as an oral small molecule by which miR-124 expression is enhanced to regulate inflammatory responses. Additional indications are addressed through ongoing product development.
Abivax offers Obefazimod and Proprietary Chemical Library.
Yes, Abivax is publicly traded on EURONEXT under the ticker symbol ABVX.
Abivax has 14 investors. Key investors include Bpifrance, Truffle Capital, TCG Crossover, Invus, and Deep Track Capital.